Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCA Healthcare, Inc.HCA · Entity 2929 | SVP-Clinical Excellence | February 22, 2018 | February 26, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCA Healthcare, Inc.
Report date February 22, 2018 · Filed February 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,003 |
Ending reported balance
After 2018-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2018-02-22 · Grant · Acquired 8,800 · Balance 9,151 F1: On February 4, 2015, the reporting person was granted 4,400 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2015-2017. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2015-2017 earnings per share, the number of performance share units that vested equaled two times the units granted. Row 2 · 2018-02-22 · Grant · Acquired 300 · Balance 9,451 F2: On February 5, 2014, the reporting person was granted 2,000 restricted stock units. The restricted stock units were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the restricted stock units subject to such criteria vested, resulting in the vesting of 300 restricted stock units. Row 3 · 2018-02-22 · Tax withholding · Disposed 3,151 · Balance 6,300 Row 4 · 2018-02-25 · Exercise / conversion · Acquired 930 · Balance 7,230 F3: Restricted stock units convert into common stock on a one-for-one basis. Row 5 · 2018-02-25 · Tax withholding · Disposed 227 · Balance 7,003 |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $47.97 · Expires 2024-02-05 | Direct | 1,050 |
Reported balance
After 2018-02-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-02-22 · Grant · Acquired 1,050 · Balance 1,050 F4: On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,050 stock appreciation rights. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-25 | Direct | 930 |
Reported balance
After 2018-02-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-02-25 · Exercise / conversion · Disposed 930 · Balance 930 F3: Restricted stock units convert into common stock on a one-for-one basis. F5: On February 25, 2016, the reporting person was granted 1,860 restricted stock units, vesting in two equal annual installments beginning on the second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 4, 2015, the reporting person was granted 4,400 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2015-2017. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2015-2017 earnings per share, the number of performance share units that vested equaled two times the units granted.
F2: On February 5, 2014, the reporting person was granted 2,000 restricted stock units. The restricted stock units were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the restricted stock units subject to such criteria vested, resulting in the vesting of 300 restricted stock units.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,050 stock appreciation rights.
F5: On February 25, 2016, the reporting person was granted 1,860 restricted stock units, vesting in two equal annual installments beginning on the second anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2017 Filed Feb 4, 2017 00:26 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | SaleCommon Stock | 15,901 | $82.00 | $1,303,882.00 |
DisclosureSEC source: 0001209191-17-007894 · doc4.xml · nonDerivative · entry 1 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,247.0531 F1 · kind: The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 2,750 | $0.00 Strike: $68.96 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 12 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 2,750 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on February 4, 2016. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 3,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 11 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2024-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on February 5, 2015. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 3,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 10 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2024-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. EBITDA performance criteria for 2014 and 2015 was met, resulting in the vesting of 3,500 stock appreciation rights. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 6,375 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 9 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125 Underlying: Common Stock · 6,375 shares Expires 2023-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on February 6, 2014. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 6,375 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 8 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,375 shares Expires 2023-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. EBITDA performance criteria for 2013, 2014 and 2015 was met, resulting in the vesting of 6,375 stock appreciation rights. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 10,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 7 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The stock appreciation right vested in four equal annual installments beginning on February 8, 2013. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionStock Appreciation Right · Derivative | 10,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · derivative · entry 6 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The stock appreciation rights vested at the end of fiscal years 2012, 2013, 2014 and 2015 based upon the achievement of certain annual EBITDA performance targets. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Tax withholdingCommon Stock | 26,599 | $80.93 | $2,152,657.07 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · nonDerivative · entry 5 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,148.0531 F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 568.0531 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionCommon Stock | 2,750 | $68.96 | $189,640.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · nonDerivative · entry 4 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,747.0531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 568.0531 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionCommon Stock | 7,000 | $47.97 | $335,790.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · nonDerivative · entry 3 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,997.0531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 568.0531 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionCommon Stock | 12,750 | $37.18 | $474,045.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · nonDerivative · entry 2 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,997.0531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 568.0531 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 00:55 UTC | HCA Healthcare, Inc. HCA · Entity 2929 | Exercise / conversionCommon Stock | 20,000 | $22.95 | $459,000.00 |
DisclosureSEC source: 0001209191-17-004684 · doc4.xml · nonDerivative · entry 1 Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,247.0531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 568.0531 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.